REVOLUTION MEDICINES INC (RVMD) Stock Fundamental Analysis
NASDAQ:RVMD - Nasdaq - US76155X1000 - Common Stock - Currency: USD
RVMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RVMD as it has an excellent financial health rating, but there are worries on the profitability. RVMD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year RVMD has reported negative net income.
RVMD had a negative operating cash flow in the past year.
RVMD had negative earnings in each of the past 5 years.
In the past 5 years RVMD always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -23.46%, RVMD is doing good in the industry, outperforming 75.64% of the companies in the same industry.
RVMD has a better Return On Equity (-26.49%) than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.46% | ||
| ROE | -26.49% | ||
| ROIC | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RVMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
Compared to 5 years ago, RVMD has more shares outstanding
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 12.93 indicates that RVMD is not in any danger for bankruptcy at the moment.
The Altman-Z score of RVMD (12.93) is better than 88.91% of its industry peers.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 12.93 |
ROIC/WACCN/A
WACC9.81%
2.3 Liquidity
RVMD has a Current Ratio of 14.20. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD has a Current ratio of 14.20. This is amongst the best in the industry. RVMD outperforms 86.18% of its industry peers.
RVMD has a Quick Ratio of 14.20. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD has a Quick ratio of 14.20. This is amongst the best in the industry. RVMD outperforms 86.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.2 | ||
| Quick Ratio | 14.2 |
3. Growth
3.1 Past
RVMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.52%.
The Revenue for RVMD has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-23.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.73%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, RVMD will show a very strong growth in Earnings Per Share. The EPS will grow by 23.39% on average per year.
The Revenue is expected to grow by 449.85% on average over the next years. This is a very strong growth
EPS Next Y-30.57%
EPS Next 2Y-19.05%
EPS Next 3Y-10.5%
EPS Next 5Y23.39%
Revenue Next Year2714.71%
Revenue Next 2Y869.97%
Revenue Next 3Y704.8%
Revenue Next 5Y449.85%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RVMD's earnings are expected to decrease with -10.50% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.05%
EPS Next 3Y-10.5%
5. Dividend
5.1 Amount
RVMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RVMD (8/14/2025, 3:01:35 PM)
35.51
-0.56 (-1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.9%
Inst Owner Change-0.47%
Ins Owners2.01%
Ins Owner Change2.69%
Market Cap6.61B
Analysts87.37
Price Target73.9 (108.11%)
Short Float %7.53%
Short Ratio6.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.21%
Min EPS beat(2)-11.25%
Max EPS beat(2)-3.17%
EPS beat(4)1
Avg EPS beat(4)-2.22%
Min EPS beat(4)-11.25%
Max EPS beat(4)8.02%
EPS beat(8)3
Avg EPS beat(8)-3.58%
EPS beat(12)6
Avg EPS beat(12)0.14%
EPS beat(16)7
Avg EPS beat(16)-1.53%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-32.42%
Revenue beat(12)4
Avg Revenue beat(12)-16.52%
Revenue beat(16)6
Avg Revenue beat(16)-17.87%
PT rev (1m)-0.2%
PT rev (3m)-0.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-11.11%
Revenue NY rev (3m)416.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.92 | ||
| P/tB | 3.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.5
EYN/A
EPS(NY)-5.06
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS0
BVpS12.16
TBVpS11.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.46% | ||
| ROE | -26.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.2 | ||
| Quick Ratio | 14.2 | ||
| Altman-Z | 12.93 |
F-Score3
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)128.3%
Cap/Depr(5y)124.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.73%
EPS Next Y-30.57%
EPS Next 2Y-19.05%
EPS Next 3Y-10.5%
EPS Next 5Y23.39%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2714.71%
Revenue Next 2Y869.97%
Revenue Next 3Y704.8%
Revenue Next 5Y449.85%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.65%
EBIT Next 3Y-20.64%
EBIT Next 5Y11.15%
FCF growth 1Y-58.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.01%
OCF growth 3YN/A
OCF growth 5YN/A